Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma
- 1 August 2014
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 38 (8) , 866-873
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Sites of extranodal involvement are prognostic in patients with diffuse large B‐cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results databaseAmerican Journal of Hematology, 2013
- Comparative effectiveness and cost of adding rituximab to first‐line chemotherapy for elderly patients diagnosed with diffuse large B‐cell lymphomaCancer, 2012
- Prognostic impact of extranodal involvement in diffuse large B‐cell lymphoma in the rituximab eraCancer, 2011
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2011
- Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphomaThe Korean Journal of Hematology, 2011
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisoneLeukemia & Lymphoma, 2010
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006
- Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary OriginJournal of Clinical Oncology, 2005
- Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 casesBritish Journal of Haematology, 2003